BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kariyama K, Nouso K, Wakuta A, Oonishi A, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kumada T. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. Liver Cancer 2020;9:41-9. [PMID: 32071908 DOI: 10.1159/000502479] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yi P, Liu J, Li Y, Wu B, Li J. The priority of liver resection compared with transarterial chemoembolization in hepatocellular carcinoma at BCLC B1 stage: A single-center experience. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.920976] [Reference Citation Analysis]
2 Li H, Chen S, Lu L, Hu X, Lin S, Zhu L. Decision curve analysis to identify optimal candidates of liver resection for intermediate-stage hepatocellular carcinoma with hepatitis B cirrhosis: A cohort study. Medicine (Baltimore) 2022;101:e31325. [PMID: 36316942 DOI: 10.1097/MD.0000000000031325] [Reference Citation Analysis]
3 Zhang N, Zhou J, Zhou Y, Guan F. MicroRNA-148a Inhibits Hepatocellular Carcinoma Cell Growth via Epithelial-to-Mesenchymal Transition and PI3K/AKT Signaling Pathways by Targeting Death Receptor-5. Appl Biochem Biotechnol 2022. [PMID: 35267120 DOI: 10.1007/s12010-022-03863-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Takaura K, Kurosaki M, Inada K, Kirino S, Yamashita K, Muto T, Osawa L, Sekiguchi S, Hayakawa Y, Higuchi M, Kaneko S, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Tsuchiya K, Nakanishi H, Takahashi Y, Izumi N. The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy. PLoS ONE 2022;17:e0264075. [DOI: 10.1371/journal.pone.0264075] [Reference Citation Analysis]
5 Lu L, Zheng P, Wu Z, Chen X. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol 2021;11:618937. [PMID: 34778022 DOI: 10.3389/fonc.2021.618937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hsu WF, Chang KC, Chen TH, Lin CH, Lin YC, Tsai MH, Chen PY, Wang HW, Chu CS, Peng CY. Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27000. [PMID: 34414987 DOI: 10.1097/MD.0000000000027000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sulaiman AS, Gani RA, Hasan I, Lesmana CRA, Kurniawan J, Jasirwan COM, Kalista KF, Nababan SHH, Aprilicia G, Lesmana LA. Overall Survival of Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation (RFA) Treatment: a Retrospective Cohort Study from Two Referral Hospitals in Indonesia. J Gastrointest Cancer 2021. [PMID: 34379264 DOI: 10.1007/s12029-021-00676-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Brunese L, Mercaldo F, Santone A, Vanoli GP. Thermal Ablation Treatment Detection by means of Machine Learning. 2021 International Joint Conference on Neural Networks (IJCNN) 2021. [DOI: 10.1109/ijcnn52387.2021.9533696] [Reference Citation Analysis]
9 Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver? Ultrasound Med Biol 2021;47:2930-5. [PMID: 34266681 DOI: 10.1016/j.ultrasmedbio.2021.05.004] [Reference Citation Analysis]
10 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Minami Y, Minami T, Ueshima K, Yagyu Y, Tsurusaki M, Okada T, Hori M, Kudo M, Murakami T. Three-Dimensional Radiological Assessment of Ablative Margins in Hepatocellular Carcinoma: Pilot Study of Overlay Fused CT/MRI Imaging with Automatic Registration. Cancers (Basel) 2021;13:1460. [PMID: 33806751 DOI: 10.3390/cancers13061460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Minami Y, Kudo M. Image Guidance in Ablation for Hepatocellular Carcinoma: Contrast-Enhanced Ultrasound and Fusion Imaging. Front Oncol 2021;11:593636. [PMID: 33747913 DOI: 10.3389/fonc.2021.593636] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
13 Li Z, Jiao D, Han X. Comment on the Manuscript "Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies". Liver Cancer 2021;10:161-2. [PMID: 33977092 DOI: 10.1159/000513719] [Reference Citation Analysis]
14 Wang X, Yang X, Chen F, Wu S, Song Z, Fei J. Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research. Can J Gastroenterol Hepatol 2021;2021:8864655. [PMID: 33505945 DOI: 10.1155/2021/8864655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Hara K, Chuma M, Eriguchi T, Tsurugai Y, Maeda S. Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma. PLoS One 2021;16:e0245076. [PMID: 33400718 DOI: 10.1371/journal.pone.0245076] [Reference Citation Analysis]
16 Tsuchiya K, Ohki T, Sato K, Kondo M, Toda N, Tagawa K. Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years. Liver Research 2020;4:206-11. [DOI: 10.1016/j.livres.2020.11.005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhou Q, Tuo F, Li R, Wang X, Wang J, Huang Z, Chen M, Huang J. Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Front Oncol 2020;10:578763. [PMID: 33251141 DOI: 10.3389/fonc.2020.578763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lu L, Zheng P, Wu Z, Chen X. Hepatic resection versus transarterial chemoembolization for the intermediate stage hepatocellular carcinoma: A cohort study.. [DOI: 10.1101/2020.10.18.20214833] [Reference Citation Analysis]
19 Chen S, Lu L, Hu X, Lin S, Zhu L. Decision curve analysis to identify optimal candidates of liver resection for intermediate-stage hepatocellular carcinoma with hepatitis B cirrhosis : A cohort study.. [DOI: 10.1101/2020.10.07.20166769] [Reference Citation Analysis]
20 Nouso K, Ohki T, Yamashita T, Takaki H, Liu C, Kang TW, Lee DH, Lee SJ, Kulkarni S, Shree D, Tanaka M. Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. Applied Sciences 2020;10:4607. [DOI: 10.3390/app10134607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]